Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SUTRO BIOPHARMA, INC. Director's Dealing 2021

Aug 11, 2021

34319_dirs_2021-08-11_07dc54cc-d3ad-4a73-b2f0-d9da127543c0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2021-08-09

Reporting Person: Vasquez Nicki (Chief Port. Strat & Alnce Ofcr)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 7270 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $11.98 2025-05-20 Common Stock (27834) Direct
Stock Option (right to buy) $11.98 2025-09-27 Common Stock (4854) Direct
Stock Option (right to buy) $15.00 2028-09-25 Common Stock (107438) Direct
Stock Option (right to buy) $10.45 2029-01-28 Common Stock (15625) Direct
Stock Option (right to buy) $10.09 2030-01-28 Common Stock (30000) Direct
Stock Option (right to buy) $21.11 2031-03-04 Common Stock (45000) Direct
Stock Option (right to buy) $18.12 2031-07-11 Common Stock (12500) Direct
Restricted Stock Unit (RSU) $ 2022-09-26 Common Stock (5969) Direct
Restricted Stock Unit (RSU) $ 2024-01-29 Common Stock (7500) Direct
Restricted Stock Unit (RSU) $ 2025-03-05 Common Stock (22000) Direct
Restricted Stock Unit (RSU) $ 2025-07-12 Common Stock (13000) Direct

Footnotes

F1: The option is fully vested and exercisable.

F2: The option vests as to 2.0833% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.

F3: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

F4: The option vests as to 2.0833% of the total shares monthly, beginning on February 29, 2020, with 100% of the total shares vested and exercisable on January 29, 2024, subject to the reporting person's provision of service to the issuer on each vesting date.

F5: The option vests as to 2.0833% of the total shares monthly, beginning on April 5, 2021, with 100% of the total shares vested and exercisable on March 5, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

F6: The option vests as to 2.0833% of the total shares monthly, beginning on August 12, 2021, with 100% of the total shares vested and exercisable on July 12, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

F7: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.

F8: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F9: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.

F10: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.

F11: The RSUs vest as to 1/4th of the total shares annually beginning on July 12, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.